ClinicalTrials.gg
RecruitingNCT07709520Updated Jul 17, 2026

Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B

A Phase 2 interventional study of GST-HG141 and GST-HG131 in Chronic Hepatitis B, sponsored by Fujian Akeylink Biotechnology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Fujian Akeylink Biotechnology Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
35 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 375 studies in Hepatitis B, Chronic with a site in China — 89 open to participants now, 110 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Planned enrollment
190th of 273
80 · median 120
Started
2026
with 26 others
Phase 2
72 of 375
15 open now
Primary completion
2026-10
later than 37 of 109 live
Registered
363rd of 375
by date

Among the 375 studies in Hepatitis B, Chronic with a site in China, this one is the 190th largest by planned enrollment of the 273 interventional ones that give a count, is one of 27 that started in 2026, is one of 72 in phase 2, reaches primary completion later than 37 of the 109 other live ones, and was the 363rd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

89 of the 375 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

83 more — sign in →

All 89 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 35 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of GST-HG131/GST-HG141 tablets in patients with chronic hepatitis B

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to sign the form and fully understand the test content, process and possible adverse reactions.
  2. Males and females aged 35-65 years(inclusive),able to complete research in accordance with test plan requirements.
  3. Participants who have no childbearing plan in a year,and must agree to voluntarily use the methods specified in the protocol from screening to 6 months after the last dose of the study.
  4. Male body weight ≥ 50 kg, female body weight ≥ 45 kg, with a (BMI) of 18-30 kg/m2 (inclusive).
  5. Participants who have received stable NA therapy for more than half a year, and have maintained the NA regimen for ≥3 months prior to Screening.
  6. concentration must be adequately suppressed, defined as At least two tests within 28 days of the screening period (more than 1 week apart) with HBV DNA lower than LLOQ .
  7. HBeAg negative, 100≤HBsAg ≤1500 IU/mL, serum (ALT)\<1×(ULN) during screening.
  8. Able to communicate well with clinical staff and complete the trial according to protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Participants with a history of allergy to any component of the product, or allergic diathesis (allergies to multiple drugs and foods).
  2. Participants unable to tolerate venous blood collection, or with a history of needle syncope or blood phobia.
  3. Participants who sustained major trauma or underwent major surgery within 3 months prior to screening, or those planning to undergo surgery during the study period.
  4. Participants with a history of alcohol abuse (defined as alcohol intake >14 standard units per week; one standard unit equals 350 mL beer, 120 mL wine, or 30 mL spirits with 40% alcohol by volume) or drug abuse/dependence at screening.
  5. Participants who participated in a clinical trial of any medicinal product or medical device (excluding in vitro diagnostic reagents) and received the investigational product or device within 3 months prior to study drug administration.
  6. Participants who received any anti- medications other than nucleos(t)ide analogues (NUCs), including marketed and unapproved agents, within 6 months prior to study drug administration.
  7. Participants who received , immunomodulators (thymosin, interferons) or cytotoxic drugs within 6 months before study drug administration; or patients who received or live vaccines within 1 month prior to screening.
  8. Participants with acute or chronic liver disease unrelated to HBV infection (non-alcoholic fatty liver disease shall be assessed by the investigator for exclusion eligibility).
  9. Participants with a medical history of liver cirrhosis or progressive liver fibrosis, defined as: liver histopathology confirming cirrhosis; endoscopy showing esophageal and gastric varices; or liver stiffness measurement (LSM) ≥9.0 kPa on transient elastography at screening.
  10. Participants with confirmed or suspected decompensated HBV-related cirrhosis, including but not limited to hepatic encephalopathy, hepatorenal syndrome, variceal bleeding of esophagus and stomach, splenomegaly, ascites, and primary liver cancer.
  11. Participants with concurrent malignant tumors or a history of other within 5 years prior to screening (excluding cured basal cell carcinoma or squamous cell carcinoma of the skin and carcinoma in situ of the cervix); participants complicated with unstable cardiovascular and cerebrovascular diseases, uncontrolled diabetes ( >7%), hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg, deemed ineligible by the investigator for study participation), or other relevant comorbidities.
  12. Participants judged by the investigator to have gastrointestinal impairment or disorders that may interfere with oral drug absorption, including severe gastrointestinal diseases (peptic ulcer, erosive or atrophic gastritis), partial gastrectomy, or gastrointestinal symptoms graded >Grade 2 per (CTCAE) at screening (e.g., nausea, vomiting, diarrhea).
  13. Participants with suspected or confirmed acute or chronic infection within 2 weeks prior to randomization.
  14. Abnormal laboratory parameters meeting any of the following thresholds:

    count \<100×10⁹/L; White blood cell count \<3.0×10⁹/L; \<1.3×10⁹/L; Serum total >2× (ULN); Serum albumin \<35 g/L; ≤60 mL/min (calculated via the equation); (INR) of prothrombin time >1.5.

  15. Participants with alpha-fetoprotein (AFP) >50 µg/L or imaging suggestive of suspected malignant hepatic space-occupying lesions.
  16. Participants positive for virus antibody (HCV-Ab); positive for Treponema pallidum antibody (TP-Ab) with positive rapid plasma reagin (RPR) test; or positive for antibody (HIV-Ab).
  17. Female participants with positive serum pregnancy test at screening or baseline, or breastfeeding women.
  18. Any other conditions deemed by the investigator to impair the participant's ability to provide or comply with the study protocol; participants judged unsuitable for trial participation; or circumstances where participation may compromise trial integrity or personal safety.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Experimental

    GST-HG141/GST-HG131

    Drug: GST-HG141 · Drug: GST-HG131

  • Placebo comparator
    Placebo 1

    GST-HG141 Placebo /GST-HG131

    Drug: GST-HG131 · Drug: GST-HG141 Placebo

  • Placebo comparator
    Placebo 2

    GST-HG141 Placebo/GST-HG131

    Drug: GST-HG131 · Drug: GST-HG141 Placebo

Interventions

  • GST-HG141 is a novel, potent and selective HBV CAM, which has a distinct molecular mechanism of its antiviral action compared to other CAMs reported in the literature, and has demonstrated strong antiviral properties in pre-clinical studies in vitro and in vivo.

  • DrugGST-HG131

    GST-HG131 is a novel dihydroquinolizinone (DHQ) compound, has been shown to reduce circulating levels of HBsAg in animals.

  • DrugGST-HG141 Placebo

    GST-HG141 Placebo

06

What researchers measure

Primary outcomes

  1. HBsAg decline from baseline at D168

    Time frame: : Baseline and up to 168 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Oct 2026, 2 months later.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's planned 2 months is below that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2026
First posted
Jul 16, 2026
StartEst.
Jul 10, 2026
Primary completionEst.
Oct 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07709520
Lead sponsor
Fujian Akeylink Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Jul 10, 2026 (estimated)
Primary completion
Oct 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jul 17, 2026

Study contacts

zhang tianxiang
Contact
zhangtianxiang@akeylink.cn
13247651892

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Neracorvir

Start the discussion